Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Aponermin-based regimen as bridging therapy prior to CAR-T cell therapy for relapsed/refractory multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

JLJuan Li

Discussion

Loading...

Member takes

Overview

Case report shows Aponermin regimen reduces minimal residual disease in multiple myeloma, suggesting it may enhance CAR-T therapy.

Key Points

  • Evaluate the efficacy and safety of Aponermin-based regimen as bridging therapy before CAR-T cell therapy in multiple myeloma.
  • Observed a case of a 48-year-old male with relapsed multiple myeloma
  • Administered Aponermin, Selinexor, and dexamethasone as bridging therapy
  • Evaluated minimal residual disease and response to CAR-T therapy
  • Minimal residual disease converted from positive to negative post-Aponermin therapy
  • Patient experienced mild cytokine release syndrome during CAR-T therapy
  • Sustained MRD negativity was achieved at follow-up

Cite This Study

Juan Li (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e503https://doi.org/10.1182/blood-2025-7534
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Safety and efficacy of aponermin-based chemotherapy as bridging therapy before CAR-T cell treatment in relapsed/refractory multiple myeloma2025
  2. 2Efficacy and safety of aponermin-carfilzomib-dexamethasone-based regimens for relapsed/refractory multiple myeloma: A Phase 2 prospective multi-center study2025
  3. 3Real-world safety and efficacy of aponermin and daratumumab-based regimens in patients with multiple myeloma2025
  4. 4Bridging Therapy's effects on clinical outcomes after commercial BCMA CAR T-cell therapy used in the standard of care treatment of relapsed and refractory multiple myeloma2025
  5. 5Aponermin combined with carfilzomid-pomalidomide-dexamethasone (KPd) in patients with relapsed or refractory multiple myeloma: A prospective, open-label, multicenter study2025